UroGen Pharma Ltd. (NASDAQ:URGN) to Post Q2 2022 Earnings of ($1.69) Per Share, Jefferies Financial Group Forecasts

UroGen Pharma Ltd. (NASDAQ:URGNGet Rating) – Research analysts at Jefferies Financial Group dropped their Q2 2022 earnings estimates for shares of UroGen Pharma in a research report issued on Wednesday, May 11th. Jefferies Financial Group analyst C. Howerton now anticipates that the company will post earnings of ($1.69) per share for the quarter, down from their previous estimate of ($1.60). Jefferies Financial Group also issued estimates for UroGen Pharma’s Q3 2022 earnings at ($1.70) EPS, Q4 2022 earnings at ($1.67) EPS, FY2022 earnings at ($5.78) EPS, FY2023 earnings at ($3.79) EPS, FY2024 earnings at ($2.45) EPS and FY2025 earnings at ($0.74) EPS.

Several other analysts have also recently issued reports on the company. The Goldman Sachs Group raised their target price on UroGen Pharma from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 22nd. Zacks Investment Research cut UroGen Pharma from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Berenberg Bank assumed coverage on UroGen Pharma in a research note on Wednesday, April 27th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, HC Wainwright cut their target price on UroGen Pharma from $34.00 to $26.00 in a research note on Tuesday, March 22nd.

UroGen Pharma stock opened at $6.23 on Friday. The firm has a market cap of $130.21 million, a P/E ratio of -1.26 and a beta of 1.41. UroGen Pharma has a 1-year low of $5.61 and a 1-year high of $19.66. The firm has a 50-day moving average of $7.88 and a 200-day moving average of $9.50.

UroGen Pharma (NASDAQ:URGNGet Rating) last released its quarterly earnings data on Monday, March 21st. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.09). The company had revenue of $16.17 million for the quarter, compared to analysts’ expectations of $16.15 million. UroGen Pharma had a negative net margin of 230.67% and a negative return on equity of 256.66%.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in UroGen Pharma by 11.9% in the first quarter. Bank of New York Mellon Corp now owns 67,486 shares of the company’s stock worth $588,000 after buying an additional 7,197 shares during the period. JPMorgan Chase & Co. lifted its holdings in UroGen Pharma by 30.8% in the first quarter. JPMorgan Chase & Co. now owns 81,867 shares of the company’s stock worth $714,000 after buying an additional 19,280 shares during the period. GSA Capital Partners LLP lifted its holdings in UroGen Pharma by 46.5% in the first quarter. GSA Capital Partners LLP now owns 57,224 shares of the company’s stock worth $498,000 after buying an additional 18,160 shares during the period. Swiss National Bank lifted its holdings in UroGen Pharma by 9.1% in the first quarter. Swiss National Bank now owns 47,900 shares of the company’s stock worth $417,000 after buying an additional 4,000 shares during the period. Finally, Rice Hall James & Associates LLC lifted its holdings in UroGen Pharma by 6.5% in the first quarter. Rice Hall James & Associates LLC now owns 107,990 shares of the company’s stock worth $941,000 after buying an additional 6,631 shares during the period.

UroGen Pharma Company Profile (Get Rating)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

Further Reading

Earnings History and Estimates for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.